NASDAQ · AKBA

Akebia Therapeutics, Inc.

Closing price · Nov 13, 2026 $0.4742
Last insider buy price $1.25 Paid by CEO and President, Director John Butler on Mar 4, 2026 (Form 4). Not today's price.

Latest quarter · ended Sep 30, 2026

Sales slipped and cash got weaker

descriptionFiled Nov 5, 2026
Revenue growthShrinking
−37.2%
Quarter ended Dec 31, 2024: −17.3% sales vs. a year beforeQuarter ended Mar 31, 2025: +75.8% sales vs. a year beforeQuarter ended Jun 30, 2025: +43.1% sales vs. a year beforeQuarter ended Sep 30, 2025: +57.0% sales vs. a year beforeQuarter ended Dec 31, 2025: +23.9% sales vs. a year beforeQuarter ended Mar 31, 2026: −6.6% sales vs. a year beforeQuarter ended Jun 30, 2026: −21.4% sales vs. a year beforeQuarter ended Sep 30, 2026: −37.2% sales vs. a year before
Dec '24Sep '26
$36.9M vs. $58.8M a year ago
Cash from operationsWorse
$2.33M
Quarter ended Dec 31, 2024: −$4.47M cash from operationsQuarter ended Mar 31, 2025: −$13.6M cash from operationsQuarter ended Jun 30, 2025: $22.3M cash from operationsQuarter ended Sep 30, 2025: $28.1M cash from operationsQuarter ended Dec 31, 2025: $31.1M cash from operationsQuarter ended Mar 31, 2026: −$21.2M cash from operationsQuarter ended Jun 30, 2026: $3.52M cash from operationsQuarter ended Sep 30, 2026: $2.33M cash from operations
Dec '24Sep '26
−92% from $28.1M a year ago
Share countDiluting
+4.6%
Quarter ended Dec 31, 2024: 236.23M sharesQuarter ended Mar 31, 2025: 262.64M sharesQuarter ended Jun 30, 2025: 265.15M sharesQuarter ended Sep 30, 2025: 265.37M sharesQuarter ended Dec 31, 2025: 267.88M sharesQuarter ended Mar 31, 2026: 268.26M sharesQuarter ended Jun 30, 2026: 277.11M sharesQuarter ended Sep 30, 2026: 277.66M shares
Dec '24Sep '26
277.66M shares vs. 265.37M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Mixed Insiders: as of Nov 13 Funds: as of Jun 30, 2026
−1000+100 0
  • info
    No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

171 funds report owning AKBA, up from 170

Holdings as of Jun 30, 2026
New39
Added61
Held37
Trimmed34
Sold out38

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale
CEOCFOOther officersDirectorsDecJanFebMarAprMayJunJulAugSepOctNovStock grant · Jan 30 · 677,000 sh · 4 peopleStock grant · Jan 30 · 743,000 shStock grant · Jan 30 · 204,000 shPlanned sale (10b5-1) · Feb 2 · $378K · 4 peoplePlanned sale (10b5-1) · Feb 2 · $474KStock grant · Feb 2 · $247KPlanned sale (10b5-1) · Feb 2 · $48.6KStock grant · Jun 17 · 214,200 sh · 6 peoplePlanned sale (10b5-1) · Jun 29 · $62.2KOption exercise · Aug 6 · $220KOpen-market buy · Mar 4 · $86.6K
CEOCFOOther officersDirectorsDecFebAprJunAugOctStock grant · Jan 30 · 677,000 sh · 4 peopleStock grant · Jan 30 · 743,000 shStock grant · Jan 30 · 204,000 shPlanned sale (10b5-1) · Feb 2 · $378K · 4 peoplePlanned sale (10b5-1) · Feb 2 · $474KStock grant · Feb 2 · $247KPlanned sale (10b5-1) · Feb 2 · $48.6KStock grant · Jun 17 · 214,200 sh · 6 peoplePlanned sale (10b5-1) · Jun 29 · $62.2KOption exercise · Aug 6 · $220KOpen-market buy · Mar 4 · $86.6K

Last 12 months. No real trades in the last 6.

Showing 1 real trade. Hidden: 13 stock grants, 1 option exercise, 7 planned 10b5-1 sales. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Mar 4 John Butler CEO and President, Director Open-market buy $86.6K 69,270 sh at $1.25

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in AKBA

As of Jun 30, 2026
FundOwnsValueChange
BlackRock, Inc.7.2%$22.8M+7%
Vanguard Capital Management LLC4.1%$12.9M+1%
AQR Capital Management LLC3.3%$10.4M+411%
Geode Capital Management, LLC2.4%$7.67M+4%
State Street Corp1.9%$6.15M−54%

"Owns" is shares reported divided by shares outstanding.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist